Monday, February 10, 2025
spot_imgspot_img

Top 5 This Week

spot_imgspot_img

Related Posts

Study reveals that gender-affirming medication is taken by fewer than 0.1% of U.S. minors


A recent study published in JAMA Pediatrics found that less than 0.1% of adolescents in the United States who are transgender or gender-diverse are prescribed puberty blockers or gender-affirming hormones. The study analyzed private insurance claims for more than 5.1 million young patients from 2018 to 2022 and found that no transgender patients under 12 were prescribed gender-affirming hormones. The use of puberty blockers and hormones was more common among trans minors assigned female sex at birth. Despite support for gender-affirming care from major medical organizations, access to such care is limited.

Dr. Alex S. Keuroghlian, director of education and training at Fenway Health, noted that there are barriers at the family and practice levels preventing transgender and gender-diverse youth from accessing gender-affirming care. This limited access is reflected in the findings of the study.

The study comes amidst ongoing debates around access to transition-related care for minors. In the U.S., more than two dozen states have restrictions on such care, and the Supreme Court recently heard arguments on the constitutionality of a Tennessee law prohibiting gender-affirming care for minors. Last month, the UK instituted an indefinite ban on new prescriptions of puberty blockers for minors, citing weak medical evidence.

Overall, the study highlights the challenges faced by transgender and gender-diverse youth in accessing gender-affirming care and underscores the ongoing debates and legal battles surrounding this issue in the U.S. and internationally.

Photo credit
www.nbcnews.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular Articles